ABEONA THERAPEUTICS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.54 USD | +8.59% |
|
-52.99% | -30.94% |
| 23/04 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
| 23/04 | Top Midday Decliners | MT |
| Sales 2024 * | 500K 41.72M | Sales 2025 * | 22.83M 1.9B | Capitalization | 89.18M 7.44B |
|---|---|---|---|---|---|
| Net income 2024 * | -60M -5.01B | Net income 2025 * | -63M -5.26B | EV / Sales 2024 * | 178 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.91 x |
| P/E ratio 2024 * |
-1.53
x | P/E ratio 2025 * |
-1.72
x | Employees | 84 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Abeona Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | +8.90% | ||
| 1 week | -52.99% | ||
| Current month | -52.27% | ||
| 1 month | -55.18% | ||
| 3 months | -28.66% | ||
| 6 months | -8.70% | ||
| Current year | -30.94% |
1 week
3.05
4.25
1 month
3.058.45
Current year
3.059.01
1 year
2.839.01
3 years
2.1951.00
5 years
2.19205.56
10 years
2.19650.00
| Managers | Title | Age | Since |
|---|---|---|---|
Vishwas Seshadri
CEO | Chief Executive Officer | 48 | 01/21/01 |
Michael Amoroso
CHM | Chairman | 46 | 09/20/09 |
Joseph Vazzano
DFI | Director of Finance/CFO | 40 | 14/22/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Alvino
BRD | Director/Board Member | 56 | 01/06/01 |
Faith Charles
BRD | Director/Board Member | 62 | 25/21/25 |
Leila Alland
BRD | Director/Board Member | 61 | 19/21/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 3.51 | +7.67% | 130 316 |
| 26/24/26 | 3.26 | +2.19% | 1,210,920 |
| 25/24/25 | 3.19 | +0.63% | 1,104,119 |
| 24/24/24 | 3.17 | -7.04% | 2,219,367 |
| 23/24/23 | 3.41 | -53.67% | 5,512,776 |
Delayed Quote Nasdaq, April 29, 2024 at 07:04 pm IST
More quotes
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Companyâs lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Companyâs fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Companyâs development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Companyâs novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.26
USD
Average target price
19.5
USD
Spread / Average Target
+498.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.94% | 89.18M | |
| +2.37% | 42.75B | |
| +48.04% | 41.61B | |
| +11.94% | 41.34B | |
| -12.36% | 26.59B | |
| +8.52% | 25.49B | |
| -24.25% | 18.12B | |
| +30.20% | 12.24B | |
| -1.84% | 11.76B | |
| +7.64% | 11B |
- Stock Market
- Equities
- ABEO Stock
